BRIEFLY / BIOTECHNOLOGY : Genentech COO to Become ViroLogic’s CEO

Genentech Inc. said Chief Operating Officer William Young resigned to become chief executive of closely held ViroLogic Inc., ending a 19-year career at the biotechnology company. Genentech, which is majority-owned by Swiss drug maker Roche Holding, also named Chief Executive Arthur Levinson to the position of chairman and announced the appointment of two outside directors. Roche sold 22 million shares to the public in July after exercising an option to acquire all of South San Francisco-based Genentech, founded in 1976 as one of the world’s first biotech companies. Levinson and Young couldn’t be reached for comment. Genentech shares rose $5.44 to close at $166 on the NYSE.